Phase 1/2a Study of BAL101553 as 48-hour Infusions in Patients With Advanced Solid Tumors or Recurrent Glioblastoma
Status:
Completed
Trial end date:
2020-08-07
Target enrollment:
Participant gender:
Summary
Single-agent, open-label, multi-center sequential dose escalation and expansion study of
BAL101553, administered as an intravenous (IV) infusion over 48 hours to adults with advanced
or recurrent solid tumors or recurrent glioblastoma.